Beyond Doublet Chemotherapy for Advanced Non–Small-Cell Lung Cancer: Combination of Targeted Agents with First-Line Chemotherapy
- 1 January 2009
- journal article
- review article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 10 (1) , 20-27
- https://doi.org/10.3816/clc.2009.n.003
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Matrix metalloproteinase-induced epithelial–mesenchymal transition: Tumor progression at Snail's paceThe International Journal of Biochemistry & Cell Biology, 2007
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of lifeThorax, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975Journal of Clinical Oncology, 2003
- Antisense strategies targeting protein kinase C: preclinical and clinical developmentSeminars in Oncology, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971